← Patent-cliff monitor small molecule SUBLOCADE BUPRENORPHINE
Loss of exclusivity November 2035 latest FDA-listed patent expiry
Company Indivior → See this company's full patent-cliff portfolio Drug detail Brand name SUBLOCADE Active ingredient BUPRENORPHINE Strength 100MG/0.5ML (100MG/0.5ML) Dosage form SOLUTION, EXTENDED RELEASE Route SUBCUTANEOUS Modality Small molecule FDA approval November 2017 Marketing status RX
Listed patents Patent Expires Type 11000520 November 2035 use U-3111 11839611 November 2035 use U-3111 12622904 November 2035 use U-4528 8921387 January 2032 product 8975270 September 2031 product 10558394 June 2031 product 9498432 June 2031 product 9782402 June 2031 product 9272044 June 2031 use U-2177 10198218 June 2031 use U-2489 9827241 June 2031 product 10592168 June 2031 use U-2489
Regulatory exclusivity Code Expires M-314 February 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.